Zobrazeno 1 - 10
of 576
pro vyhledávání: '"Apperley, JF"'
Publikováno v:
Expert Review of Hematology; May2023, Vol. 16 Issue 5, p325-332, 8p
Autor:
Tamaddon, M, Burrows, M, Ferreira, SA, Dazzi, F, Apperley, JF, Bradshaw, A, Brand, DD, Czernuszka, J, Gentleman, E
Publikováno v:
Scientific Reports
Tamaddon, M, Burrows, M, Ferreira, S A, Dazzi, F, Apperley, J F, Bradshaw, A, Brand, D D, Czernuszka, J & Gentleman, E 2017, ' Monomeric, porous type II collagen scaffolds promote chondrogenic differentiation of human bone marrow mesenchymal stem cells in vitro ', Scientific Reports, vol. 7, 43519 . https://doi.org/10.1038/srep43519
Tamaddon, M, Burrows, M, Ferreira, S A, Dazzi, F, Apperley, J F, Bradshaw, A, Brand, D D, Czernuszka, J & Gentleman, E 2017, ' Monomeric, porous type II collagen scaffolds promote chondrogenic differentiation of human bone marrow mesenchymal stem cells in vitro ', Scientific Reports, vol. 7, 43519 . https://doi.org/10.1038/srep43519
Osteoarthritis (OA) is a common cause of pain and disability and is often associated with the degeneration of articular cartilage. Lesions to the articular surface, which are thought to progress to OA, have the potential to be repaired using tissue e
Autor:
Nicolini, FE, Basak, GW, Kim, DW, Olavarria, E, Pinilla-Ibarz, J, Apperley, JF, Hughes, T, Niederwieser, D, Mauro, MJ, Chuah, C, Hochhaus, A, Martinelli, G, DerSarkissian, M, Duh, MS, McGarry, LJ, Kantarjian, HM, Cortes, JE
Publikováno v:
Cancer
BACKGROUND Effective treatment options for patients with chronic myeloid leukemia (CML) or Philadelphia‐positive (Ph+) acute lymphoblastic leukemia (ALL) who have the threonine to isoleucine mutation at codon 315 (T315I) are few. The objective of t
Autor:
Claudiani, S, Apperley, JF, Deplano, S, Khorashad, J, Foroni, L, Palanicawandar, R, Perry, R, Milojkovic, D
Publikováno v:
E481
E480
E480
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1032::40c18ee5002504439a9a6e1bbbffe497
http://hdl.handle.net/10044/1/38635
http://hdl.handle.net/10044/1/38635
Publikováno v:
21st Congress of the European Hematology Association
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1032::ab3ed8d9b721c0da12997e9f3335712d
http://hdl.handle.net/10044/1/40380
http://hdl.handle.net/10044/1/40380
Autor:
Cortes, JE, Pinilla-Ibarz, J, Le Coutre, PD, Paquette, R, Chuah, C, Nicolini, FE, Apperley, JF, Khoury, HJ, Talpaz, M, Baccarani, M, Lustgarten, S, Haluska, FG, Guilhot, F, Deininger, MW, Hochhaus, A, Hughes, TP, Shah, NP, Kantarjian, HM
Publikováno v:
21st Congress of the European Hematology Association
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1032::a19a096480f8c3953e7ffeccf0d9d2ed
http://hdl.handle.net/10044/1/40379
http://hdl.handle.net/10044/1/40379
Autor:
Paul, DS, Jones, A, Sellar, RS, Mayor, NP, Feber, A, Webster, AP, Afonso, N, Sergeant, R, Szydlo, RM, Apperley, JF, Widschwendter, M, Mackinnon, S, Marsh, SGE, Madrigal, JA, Rakyan, VK, Peggs, KS, Beck, S
Background Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for many hematological conditions. Acute graft-versus-host disease (aGVHD) is a prevalent immune-mediated complication following HSCT. Current diagnostic bio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1032::d16b38b8c2cbd4e52b2aa1acb40d9958
http://hdl.handle.net/10044/1/40899
http://hdl.handle.net/10044/1/40899
Autor:
Worel, N, Apperley, Jf, Basak, Gw, Douglas, Kw, Gabriel, Ih, Geraldes, C, Hübel, K, Jaksic, O, Koristek, Z, Lanza, F, Lemoli, ROBERTO MASSIMO, Mikala, G, Selleslag, D, Duarte, Rf, Mohty, M.
BACKGROUND: Plerixafor with granulocyte-colony-stimulating factor (G-CSF) has been shown to enhance stem cell mobilization in patients with multiple myeloma and lymphoma with previous mobilization failure. In this European named patient program we re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::935b0341c37bd949bd2575eb859ff268
https://www.bib.irb.hr/682397
https://www.bib.irb.hr/682397
Autor:
Cortes, Je1, Kim, Dw, Pinilla Ibarz, J, le Coutre, P, Paquette, R, Chuah, C, Nicolini, Fe, Apperley, Jf, Khoury, Hj, Talpaz, M, Dipersio, J, Deangelo, Dj, Abruzzese, E, Rea, D, Baccarani, M, Müller, Mc, Gambacorti Passerini, C, Wong, S, Lustgarten, S, Rivera, Vm, Clackson, T, Turner, Cd, Haluska, Fg, Guilhot, F, Deininger, Mw, Hochhaus, A, Hughes, T, Goldman, Jm, Shah, Np, Kantarjian, H, Pace, Investigators, Saglio, Giuseppe
Background Ponatinib is a potent oral tyrosine kinase inhibitor of unmutated and mutated BCR-ABL, including BCR-ABL with the tyrosine kinase inhibitor–refractory threonineto-isoleucine mutation at position 315 (T315I). We conducted a phase 2 trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::468aaf98e550898d3a82c26fd1a09826
http://hdl.handle.net/10281/52070
http://hdl.handle.net/10281/52070
Autor:
Cortes, JE, Kim, D-W, Pinilla-Ibarz, J, le Coutre, P, Paquette, R, Chuah, C, Nicolini, FE, Apperley, JF, Khoury, HJ, Talpaz, M, DiPersio, J, DeAngelo, DJ, Abruzzese, E, Rea, D, Baccarani, M, Müller, MC, Gambacorti-Passerini, C, Wong, S, Lustgarten, S, Rivera, VM, Clackson, T, Turner, CD, Haluska, FG, Guilhot, F, Deininger, MW, Hochhaus, A, Hughes, T, Goldman, JM, Shah, NP, Kantarjian, H, PACE Investigators
Publikováno v:
The New England journal of medicine, vol 369, iss 19
BackgroundPonatinib is a potent oral tyrosine kinase inhibitor of unmutated and mutated BCR-ABL, including BCR-ABL with the tyrosine kinase inhibitor-refractory threonine-to-isoleucine mutation at position 315 (T315I). We conducted a phase 2 trial of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______325::7cc75f7e4e51a4a96142790ddee69076
https://escholarship.org/uc/item/6s61b8vf
https://escholarship.org/uc/item/6s61b8vf